



MOREPEN



Date: 01/07/2026

To,
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Sub.: Press Release – ‘Morepen starts commercial supplies under its ₹ 825 Crore CDMO mandate’

Dear Sir/ Madam,

Please find enclosed press release with the title ‘Morepen starts commercial supplies under its ₹ 825 Crore CDMO mandate’.

This is for your information and dissemination on your website.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

MOREPEN STARTS COMMERCIAL SUPPLIES UNDER ITS ₹ 825 CRORE CDMO MANDATE

First ₹50 crore dispatch already completed in Q1FY2026-27

Gurugram, Haryana, July 1, 2026: Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today issued an update on its recently announced ₹825 crore CDMO mandate. The first commercial dispatch, valued at approximately ₹50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage.

Commenting on the development, Mr. Sanjay Suri, Managing Director, Morepen Laboratories Limited, said, *“This is an important milestone in Morepen’s transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities.”*

Having dispatched the first batch under the CDMO mandate, Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately ₹225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements.

The Company continues to strengthen its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases.

The commencement of commercial supplies under this mandate reinforces Morepen’s strategy to build a scalable CDMO platform, deepen customer partnerships and participate in long-duration global manufacturing opportunities.

About Morepen Laboratories Limited

Morepen Laboratories Limited is a pharmaceutical and healthcare company with a presence across APIs, finished formulations, diagnostics and consumer healthcare. The Company continues to strengthen its manufacturing, research and regulatory capabilities to support growth across domestic and international markets.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



MOREPEN



Safe Harbour Statement

Certain statements in this release concerning future prospects, business plans, expectations and performance may be forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. The Company does not undertake to update any forward-looking statements except as required by applicable law.

Investors' Relations Contact:

Mr. Nishant Doshi, Head-Corporate Finance & Investor Relations;

Mobile No.: 9769633650; **Email:** nishant.doshi@morepen.com

Media Contact:

Girish Singhal

Propel Communications

Email: propelpr.com@gmail.com

Mb.: 9810206244

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, **E-mail:** corporate@morepen.com, **Website:** www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, **Fax:** +91 1795 244591, **E-mail:** plants@morepen.com